Abstract
Background and Objective: According to a European pilot study, the 308-nanometer (nm) Excilite μ™ (DEKA, Florence, Italy) system may be a promising tool for patients with vitiligo by offering targeted phototherapy, a rapid onset of repigmentation, and few adverse effects. The objective of this study was to evaluate the clinical efficacy and safety of the 308-nm Excilite μ in the treatment of vitiligo. Methods and Limitations: Ten patients with stable vitiligo were exposed to 10 weeks of targeted phototherapy with the Excilite μ device, followed by 5 weeks of observation. Skin types 1 and 2 were not included in the cohort, and Wood's light examination was not documented. Results: At 2 weeks, repigmentation was observed in 60% of the subjects, according to patient assessment, and 50% of the subjects, according to the treating physician and independent observer assessments. All patients maintained the repigmentation during the 5-week, follow-up period. Conclusion: The 308-nm Excilite μ is a safe and fast-acting therapeutic option in patients with stable vitiligo and skin types 3 through 6.
| Original language | English |
|---|---|
| Pages (from-to) | 258-263 |
| Number of pages | 6 |
| Journal | Journal of Drugs in Dermatology |
| Volume | 7 |
| Issue number | 3 |
| State | Published - Mar 1 2008 |
Fingerprint
ASJC Scopus subject areas
- Dermatology
- Medicine(all)
Cite this
A pilot study to determine the safety and efficacy of monochromatic excimer light in the treatment of vitiligo. / Chimento, Stacy M.; Newland, Meggan; Ricotti, Carlos; Nistico, Steven; Romanelli, Paolo.
In: Journal of Drugs in Dermatology, Vol. 7, No. 3, 01.03.2008, p. 258-263.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A pilot study to determine the safety and efficacy of monochromatic excimer light in the treatment of vitiligo
AU - Chimento, Stacy M.
AU - Newland, Meggan
AU - Ricotti, Carlos
AU - Nistico, Steven
AU - Romanelli, Paolo
PY - 2008/3/1
Y1 - 2008/3/1
N2 - Background and Objective: According to a European pilot study, the 308-nanometer (nm) Excilite μ™ (DEKA, Florence, Italy) system may be a promising tool for patients with vitiligo by offering targeted phototherapy, a rapid onset of repigmentation, and few adverse effects. The objective of this study was to evaluate the clinical efficacy and safety of the 308-nm Excilite μ in the treatment of vitiligo. Methods and Limitations: Ten patients with stable vitiligo were exposed to 10 weeks of targeted phototherapy with the Excilite μ device, followed by 5 weeks of observation. Skin types 1 and 2 were not included in the cohort, and Wood's light examination was not documented. Results: At 2 weeks, repigmentation was observed in 60% of the subjects, according to patient assessment, and 50% of the subjects, according to the treating physician and independent observer assessments. All patients maintained the repigmentation during the 5-week, follow-up period. Conclusion: The 308-nm Excilite μ is a safe and fast-acting therapeutic option in patients with stable vitiligo and skin types 3 through 6.
AB - Background and Objective: According to a European pilot study, the 308-nanometer (nm) Excilite μ™ (DEKA, Florence, Italy) system may be a promising tool for patients with vitiligo by offering targeted phototherapy, a rapid onset of repigmentation, and few adverse effects. The objective of this study was to evaluate the clinical efficacy and safety of the 308-nm Excilite μ in the treatment of vitiligo. Methods and Limitations: Ten patients with stable vitiligo were exposed to 10 weeks of targeted phototherapy with the Excilite μ device, followed by 5 weeks of observation. Skin types 1 and 2 were not included in the cohort, and Wood's light examination was not documented. Results: At 2 weeks, repigmentation was observed in 60% of the subjects, according to patient assessment, and 50% of the subjects, according to the treating physician and independent observer assessments. All patients maintained the repigmentation during the 5-week, follow-up period. Conclusion: The 308-nm Excilite μ is a safe and fast-acting therapeutic option in patients with stable vitiligo and skin types 3 through 6.
UR - http://www.scopus.com/inward/record.url?scp=47249161205&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=47249161205&partnerID=8YFLogxK
M3 - Article
C2 - 18380207
AN - SCOPUS:47249161205
VL - 7
SP - 258
EP - 263
JO - Journal of Drugs in Dermatology
JF - Journal of Drugs in Dermatology
SN - 1545-9616
IS - 3
ER -